RESUMEN
Introducción: Pese a que el uso de corticoides transtimpánicos en pacientes con enfermedad de Méniere es habitual en muchos centros, la evidencia respecto de su efecto sobre los umbrales auditivos es aún controversial. Objetivo: Estudiar los umbrales auditivos de pacientes con enfermedad de Méniere que recibieron corticoides transtimpánicos en el Servicio de Otorrinolaringología del Hospital Clínico de la Universidad de Chile. Material y Método: Estudio retrospectivo de pacientes con enfermedad de Méniere que consultaron entre los años 2015 y 2021. Se estudiaron los umbrales auditivos, antes y después de 3 inyecciones de dexametasona transtimpánica. Resultados: Se obtuvieron datos completos de 27 pacientes. Al comparar el promedio tonal puro antes y después del tratamiento, no se observaron diferencias significativas. A nivel individual, la variación de cambio de los umbrales auditivos con dexametasona se correlaciona en forma significativa con los umbrales auditivos previos a las inyecciones y con el tiempo transcurrido desde la última inyección, pero no con la edad. Conclusión: La terapia con dexametasona transtimpánica en pacientes con enfermedad de Méniere no altera los umbrales auditivos. Sin embargo, se requieren más estudios, para comprobar, si existe un efecto transitorio en los umbrales auditivos de los primeros días posterior al procedimiento.
Introduction: Although transtympanic corticosteroids are proposed in Méniere's disease patients refractory to standard medical therapy, the evidence regarding the effect of transtympanic corticosteroids on hearing thresholds is still controversial. Aim: To study the hearing thresholds of patients with Méniere's disease who were administrated with transtympanic corticosteroids at the Otorhinolaryngology Service of the University of Chile's Clinical Hospital. Material and Method: Retrospective study of Méniere's disease patients who consulted between 2015 and 2021. Demographic variables and hearing thresholds were studied before and after three transtympanic injections of dexamethasone. Results: A total of 27 patients were studied. There were non-significant differences in pure-tone hearing threshold averages before and after the injections. Individual variation in hearing thresholds correlates significantly with the pre-injection hearing thresholds and the period since the last injection, but not with age. Conclusion: Transtympanic dexamethasone therapy in patients with Meniere's disease does not alter hearing thresholds. However, more studies are needed to verify whether there is a transitory effect on hearing thresholds in the first days after the procedure.
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Adulto Joven , Umbral Auditivo/efectos de los fármacos , Dexametasona/uso terapéutico , Enfermedad de Meniere/tratamiento farmacológico , Antiinflamatorios/uso terapéutico , Audiometría/métodos , Chile , Estudios RetrospectivosRESUMEN
INTRODUCCION La enfermedad de Ménière es una anomalía del oído interno de etiología multifactorial, caracterizada por episodios de vértigo espontáneo y recurrente, hipoacusia fluctuante y tinnitus. La terapia con gentamicina intratimpánica para la enfermedad de Ménière ha sido utilizada buscando reducir la intensidad y frecuencia de las crisis, pero se ha asociado a pérdida auditiva, por lo que existe controversia respecto a su eficacia y seguridad. MÉTODOS Realizamos una búsqueda en Epistemonikos, la mayor base de datos de revisiones sistemáticas en salud, la cual es mantenida mediante el cribado de múltiples fuentes de información, incluyendo MEDLINE, EMBASE, Cochrane, entre otras. Extrajimos los datos desde las revisiones identificadas, analizamos los datos de los estudios primarios, realizamos un metanálisis y preparamos una tabla de resumen de los resultados utilizando el método GRADE. RESULTADOS Y CONCLUSIONES Identificamos 13 revisiones sistemáticas que en conjunto incluyeron 80 estudios primarios, de los cuales tres corresponden a ensayos aleatorizados. Concluimos que la gentamicina intratimpánica podría reducir el control del vértigo y resultar en poca o nula diferencia sobre el tinnitus, pero la certeza de evidencia es baja. Además, no es posible establecer con claridad si el uso de gentamicina intratimpánica disminuye la audición o la frecuencia de los ataques de vértigo porque la certeza de la evidencia existente ha sido evaluada como muy baja.
INTRODUCTION Ménière's disease is a multifactorial disorder affecting the inner ear, characterized by episodes of spontaneous and recurrent vertigo, fluctuating hearing loss and tinnitus. Intratympanic gentamicin therapy has been used to reduce the intensity and frequency of attacks in intractable Ménière's disease, but it is associated with hearing loss. There is controversy regarding its efficacy and safety. METHODS We searched in Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies, conducted a meta-analysis and generated a summary of findings table using the GRADE approach. RESULTS AND CONCLUSIONS We identified 13 systematic reviews that included 80 primary studies overall, of which three correspond to randomized trials. We concluded that intratympanic gentamicin may improve the control of vertigo, and result in little or no difference to tinnitus, but the certainty of the evidence is low. Furthermore, we are uncertain whether intratympanic gentamicin reduces hearing or the frequency of vertigo attacks as the certainty of the evidence has been assessed as very low.
Asunto(s)
Humanos , Acúfeno/etiología , Acúfeno/tratamiento farmacológico , Enfermedad de Meniere/tratamiento farmacológico , Gentamicinas/uso terapéutico , Vértigo/etiología , Vértigo/tratamiento farmacológico , Revisiones Sistemáticas como AsuntoRESUMEN
OBJECTIVES: To investigate the effects of an intratympanic injection of dexamethasone combined with gentamicin on the expression level of serum P0 protein antibodies in patients with Meniere's disease (MD). METHODS: A total of 136 patients with MD treated in our hospital were enrolled in this study. Among them, 68 patients were treated with an intratympanic injection of dexamethasone combined with gentamicin (observation group). Another 68 patients were treated with gentamicin alone (control group). RESULTS: After treatment, the expression levels of IgG and IgM in the two groups significantly decreased (p<0.05); the levels in the observation group were significantly lower than those in the control group (p<0.05). The incidences of vertigo, tinnitus, and gait instability in the observation group were significantly lower than those in the control group (p<0.05). Vestibular symptom index (VSI) scores in the observation group were significantly lower than those in the control group (p<0.05). We observed no significant difference between the two groups in the number of vertigo attacks 6 months after treatment (p>0.05). CONCLUSION: For patients with MD, dexamethasone combined with gentamicin can reduce the incidence of vertigo, tinnitus, and gait instability, but it has no effect on the efficacy or number of vertigo attacks 6 months after treatment. Therefore, the levels of myelin P0 protein antibodies after treatment can be used as predictors of vertigo at 6 months after treatment.
Asunto(s)
Humanos , Proteína P0 de la Mielina , Enfermedad de Meniere/tratamiento farmacológico , Dexametasona/uso terapéutico , Gentamicinas/uso terapéutico , Resultado del Tratamiento , Inyección Intratimpánica , Antibacterianos/uso terapéuticoRESUMEN
RESUMEN Introducción: La gentamicina transtimpánica se utiliza en el manejo de pacientes con vértigo crónico refractario al manejo médico. Objetivo: Describir y analizar las características clínicas, epidemiológicas, y resultados de pacientes sometidos a tratamiento con gentamicina transtimpánica en el Hospital Clínico de la Universidad de Chile. Material y método: Estudio retrospectivo, descriptivo, incluyendo los pacientes con patología otorrinolaringológica que hayan recibido gentamicina transtimpánica entre los años 2008 y 2018. Se analizaron variables epidemiológicas, clínicas, y función vestibular. Resultados: La serie está constituida por diez pacientes, con una edad promedio de 52,4 años; siete mujeres y tres hombres. El diagnóstico fue en su mayoría enfermedad de Ménière (7 pacientes). El número promedio de inyecciones de gentamicina fue de 2,8. En el período de seguimiento (rango 1-96 meses), se logró mejoría del vértigo en la mayoría de los pacientes (8 de 10). Conclusión: El tratamiento con inyecciones de gentamicina transtimpánica es una opción importante para aliviar la sintomatología de pacientes con vértigo crónico intratable. Debe indicarse en casos seleccionados, y siempre realizar un estudio auditivo y vestibular completo antes y después del tratamiento con gentamicina.
ABSTRACT Introduction: Transtympanic gentamicin is used for treatment of patients with chronic vertigo refractory to medical management. Aim: To describe and analyze the clinical outcome of patients whom underwent treatment with transtympanic gentamicin at the Clinical Hospital Universidad de Chile. Material and method: Retrospective and descriptive study including patients with otolaryngologist disease whom underwent treatment with transtympanic gentamicin between 2008 and 2018. Epidemiological, clinical variables and vestibular function were analyzed. Results: The serie consists of ten patients, 7 men and 3 women, with an average age of 52,4 years. The most frequent diagnosis was Ménière disease (7 patients). The average number of gentamicin injections was 2,8. The follow up varies from 1 to 96 months, presenting improvement of vertigo in the majority of the cases (8 of 10 patients). Conclusion: The treatment with transtympanic injections of gentamicin is a relevant option to decrease symptoms in patients with chronic intractable vertigo. It should be indicated in selected patients. Prior and posterior the treatment, patients must be studied with a complete evaluation of the auditory and vestibular function.
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Gentamicinas/uso terapéutico , Vértigo/tratamiento farmacológico , Enfermedad de Meniere/tratamiento farmacológico , Membrana Timpánica , Pruebas de Función Vestibular , Gentamicinas/administración & dosificación , Estudios Retrospectivos , Estudios de Seguimiento , Resultado del TratamientoRESUMEN
Abstract Introduction Intratympanic gentamicin regulates the symptoms in most patients with incapacitating Ménière's disease. The treatment protocols have changed over the years from medical labyrinthectomy to preservation of vestibular function. Objectives This study aims to review the audiovestibular response related to the effect of the drug in controlling vertigo. Data Synthesis Articles were identified by means of a search in the PubMed database using the key words Meniere and intratympanic or transtympanic gentamicin. Total 144 articles were reviewed after excluding those that were technical reports, those based on experimental animal studies, those that focused on outcomes other than vertigo (tinnitus or aural fullness), those with delivery methods other than tympanic membrane injection, and those with bilateral cases. If there was more than one article by the same author(s) or institution, only the most recent one matching the aforementioned criteria and those that were not overlapping were included. Conclusion Titration methods or multiple injections on a daily basis can be preferred if the patients have profound or non-serviceable hearing, since these methods have significant incidence of hearing loss. Treatment protocols with a frequency of injection not shorter than once a week, or those with injections on a monthly basis as "needed" provide the same level of vertigo control with better preservation of hearing. Caloric testing is not an ideal tool to analyze the correlation between vertigo control and the effect of gentamicin as compared with gain asymmetry of the vestibulo-ocular reflex. Vestibular-evoked myogenic potentials and the head thrust test are more reliable than other vestibular tests for the follow-up of patients undergoing gentamicin treatment.
Asunto(s)
Humanos , Gentamicinas/administración & dosificación , Gentamicinas/uso terapéutico , Vértigo/tratamiento farmacológico , Enfermedad de Meniere/tratamiento farmacológico , Audiometría , Pruebas de Función Vestibular , Vértigo/etiología , Enfermedad de Meniere/complicacionesRESUMEN
INTRODUCCIÓN: La enfermedad de Ménière es una anomalía del oído interno caracterizada por episodios de vértigo espontáneo, hipoacusia fluctuante y tinnitus. Los diuréticos han sido ampliamente utilizados para el tratamiento de las crisis de esta enfermedad, pero existe controversia respecto a su eficacia. MÉTODOS: Para responder esta pregunta utilizamos Epistemonikos, la mayor base de datos de revisiones sistemáticas en salud, la cual es mantenida mediante búsquedas en múltiples fuentes de información, incluyendo MEDLINE, EMBASE, Cochrane, entre otras. Extrajimos los datos desde las revisiones identificadas, reanalizamos los datos de los estudios primarios y preparamos una tabla de resumen de los resultados utilizando el método GRADE. RESULTADOS Y CONCLUSIONES: Identificamos tres revisiones sistemáticas que en conjunto incluyen diecinueve estudios primarios, de los cuales, cuatro son ensayos aleatorizados. Concluimos que no está claro si el uso de diuréticos lleva a una mejoría sintomática del vértigo o a una disminución objetiva de la hipoacusia en pacientes con enfermedad de Ménière, porque la certeza de la evidencia es muy baja.
INTRODUCTION: Ménière`s disease is an inner ear disorder characterized by episodes of spontaneous vertigo, fluctuating hearing loss and tinnitus. Diuretics have been widely used for the treatment of attacks, but there is controversy about their effectiveness. METHODS: To answer this question we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies, conducted a meta-analysis and generated a summary of findings table using the GRADE approach. RESULTS AND CONCLUSIONS: We identified three systematic reviews including nineteen studies overall, of which four were randomized trials. We concluded it is not clear whether diuretics lead to a symptomatic improvement of vertigo or an objective decrease in hearing loss in patients with Ménière`s disease, because the certainty of the evidence is very low.
Asunto(s)
Diuréticos/uso terapéutico , Enfermedad de Meniere/tratamiento farmacológico , Acúfeno/etiología , Acúfeno/tratamiento farmacológico , Ensayos Clínicos Controlados Aleatorios como Asunto , Vértigo/etiología , Vértigo/tratamiento farmacológico , Bases de Datos Factuales , Resultado del Tratamiento , Pérdida Auditiva/etiología , Pérdida Auditiva/tratamiento farmacológico , Enfermedad de Meniere/fisiopatologíaRESUMEN
Abstract Introduction: Even today, the treatment of intractable vertigo remains a challenge. Vestibular ablation with intratympanic gentamicin stands as a good alternative in the management of refractory vertigo patients. Objective: To control intractable vertigo through complete saccular and horizontal canal vestibular ablation with intratympanic gentamicin treatment. Methods: Patients with refractory episodic vertigo were included. The inclusion criteria were: unilateral ear disease, moderate to profound sensorineural hearing loss, and failure to other treatments. Included patients underwent 0.5-0.8 mL of gentamicin intratympanic application at a 30 mg/mL concentration. Vestibular ablation was confirmed by the absence of response on cervical vestibular evoked myogenic potentials and no response on caloric tests. Audiometry, electronystagmography with iced water, and vestibular evoked myogenic potentials were performed in all patients. Results: Ten patients were included; nine patients with Meniere's disease and one patient with (late onset) delayed hydrops. Nine patients showed an absent response on vestibular evoked myogenic potentials and no response on caloric tests. The only patient with low amplitude on cervical vestibular evoked myogenic potentials had vertigo recurrence. Vertigo control was achieved in 90% of the patients. One patient developed hearing loss >30 dB. Conclusions: Cervical vestibular evoked myogenic potentials confirmed vestibular ablation in patients treated with intratympanic gentamicin. High-grade vertigo control was due to complete saccular and horizontal canal ablation (no response to iced water in electronystagmography and no response on cervical vestibular evoked myogenic potentials).
Resumo Introdução: Ainda hoje, o controle da vertigem intratável permanece um desafio. A ablação vestibular com gentamicina intratimpânica permanece como uma boa alternativa no tratamento de pacientes com vertigem refratária. Objetivo: Controlar a vertigem intratável por meio de ablação vestibular completa dos canais sacular e horizontal com gentamicina intratimpânica como tratamento. Método: Pacientes com vertigem refratária episódica foram incluídos. Os critérios de inclusão foram doença unilateral da orelha, perda auditiva neurossensorial de moderada a profunda e fracasso com outros tratamentos. Os pacientes incluídos receberam uma aplicação de 0,5-0,8 mL de gentamicina intratimpânica com concentração de 30 mg/mL. A ablação vestibular foi confirmada pela ausência de resposta no teste de potencial evocado miogênico vestibular cervical (PEMVc) e nenhuma resposta nas provas calóricas. Audiometria, eletronistagmografia com água gelada e potencial evocado miogênico vestibular foram realizados em todos os pacientes. Resultados: Ao todo, dez pacientes foram incluídos: nove com doença de Ménière e um com hidropisia tardia. Nove pacientes apresentaram ausência de resposta no teste de potencial evocado miogênico vestibular e nenhuma resposta na prova calórica. O único paciente com baixa amplitude no PEMVc apresentou recorrência da vertigem. O controle da vertigem foi obtido em 90% dos pacientes. Um paciente desenvolveu perda auditiva > 30 dB. Conclusões: O PEMVc confirmou ablação vestibular nos pacientes tratados com gentamicina intratimpânica. O alto grau de controle da vertigem foi devido à ablação completa do sáculo e canal horizontal (sem resposta à água gelada na eletronistagmografia e ausência de resposta no PEMVc).
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Membrana Timpánica , Gentamicinas/administración & dosificación , Potenciales Vestibulares Miogénicos Evocados/efectos de los fármacos , Enfermedad de Meniere/tratamiento farmacológico , Antibacterianos/administración & dosificación , Índice de Severidad de la Enfermedad , Pruebas Calóricas , Estudios Retrospectivos , Resultado del Tratamiento , ElectronistagmografíaRESUMEN
ABSTRACT INTRODUCTION: Preventing or reversing hearing loss is challenging in Ménière's disease. Betahistine, as a histamine agonist, has been tried in controlling vertigo in patients with Ménière's disease, but its effectiveness on hearing problems is not known. OBJECTIVE: To examine the effect of betahistine on hearing function in not-previously-treated patients with Ménière's disease and to define possible contributors in this regard. METHODS: A total of 200 not-previously-treated patients with definite unilateral Ménière's disease received betahistine by mouth (initial dose, 16 mg three times a day; maintenance dose, 24-48 mg daily in divided doses). Changes in indicators of hearing status before and six months after treatment were documented. Hearing loss was considered as the mean hearing level >25 dB HL at five frequencies. RESULTS: The mean duration of disease was 3.37 years. Six months after treatment the mean hearing level decreased by 6.35 dB compared to that at the baseline (p < 0.001). Both patients' age and the duration of disease correlated negatively with the improvement in hearing function. Post treatment hearing loss was independently associated with age, the initial hearing level and the chronicity of disease. The corresponding optimal cut-off points for predicating a persistent hearing loss 6 months after treatment were 47 years, 38 dB HL, and 1.4 years, respectively. CONCLUSION: Oral betahistine was significantly effective in preventing/reversing hearing deterioration in patients with Ménière's disease. Age, the hearing level on admission, and the disease duration were independent predictors of hearing status after treatment.
Resumo Introdução: Prevenir ou reverter a perda auditiva é um desafio na doença de Ménière. A betahistina, um agonista de histamina, tem sido testada no controle de vertigem em pacientes com doença de Ménière, mas sua eficácia em problemas de audição ainda não é conhecida. Objetivo: Analisar o efeito da betahistina na função auditiva em pacientes com doença de Ménière não tratados previamente, e definir possíveis contribuintes a esse respeito. Método: Um total de 200 pacientes sem tratamento prévio, e com diagnóstico definido de doença de Ménière unilateral, recebeu beta-histina por via oral (dose inicial de 16 mg três vezes ao dia; dose de manutenção de 24-48 mg por dia, em doses divididas). Alterações dolimiar auditivo antes e após seis meses de tratamento foram documentadas. Considerou-se como perda auditiva uma média do nível de audição > 25 dB NA em cinco frequências. Resultados: A média de duração da doença foi de 3,37 anos. Seis meses após o tratamento, a média do limiar auditivo diminuiu em 6,35 dB, em comparação com o valor da linha de base (p < 0,001). Tanto a idade dos pacientes quanto a duração da doença apresentaram correlação negativa com a melhora da função auditiva. A perda auditiva após o tratamento foi independentemente associada à idade, ao nível inicial de audição e à cronicidade da doença. Os pontos de corte ótimos correspondentes para prever uma perda auditiva persistente seis meses após o tratamento foram 47 anos, 38 dB HL e 1,4 ano, respectivamente. Conclusão: A betahistina oral foi significantemente eficaz na prevenção/reversão da deterioração auditiva em pacientes com doença de Ménière. Idade, nível de audição na admissão e duração da doença foram fatores preditivos independentes da condição auditiva após o tratamento.
Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto , Persona de Mediana Edad , Anciano , Adulto Joven , Betahistina/uso terapéutico , Agonistas de los Receptores Histamínicos/uso terapéutico , Pérdida Auditiva/tratamiento farmacológico , Enfermedad de Meniere/tratamiento farmacológico , Audiometría , Resultado del Tratamiento , Otoscopía , Pérdida Auditiva/etiología , Enfermedad de Meniere/complicacionesRESUMEN
A tecnologia de realidade virtual fornece uma grande variedade de estímulos que geram conflitos sensoriais em diferentes níveis de dificuldades e em ambiente seguro. OBJETIVO: Verificar o efeito de um programa de reabilitação vestibular do equilíbrio corporal com estímulos de realidade virtual em pacientes com doença de Ménière. Forma de estudo: Estudo clínico observacional. MÉTODO: Quarenta e quatro pacientes, com idade entre 18 e 60 anos e doença de Ménière definida, distribuídos em dois grupos - experimental (GE) e controle (GC) - fizeram uso de betaistina e dieta alimentar; o grupo experimental foi submetido adicionalmente a 12 sessões de reabilitação com realidade virtual da BRU TM. Os pacientes responderam ao Dizziness Handicap Inventory (DHI), à escala analógica de tontura e realizaram a posturografia com realidade virtual antes e após a intervenção. RESULTADOS: Após a intervenção, o GE apresentou valores significantemente menores do DHI (p < 0,001) e da escala analógica de tontura (p = 0,012) e valores significantemente maiores da área do limite de estabilidade (p = 0,016), em comparação com o GC. CONCLUSÃO: A reabilitação do equilíbrio corporal com estímulos de realidade virtual é eficaz na melhora da tontura, da qualidade de vida e do limite de estabilidade de pacientes com doença de Ménière.
Virtual reality technology can provide a wide range of sensory stimuli to generate conflicts of varying degrees of complexity in a safe environment. OBJECTIVE: To verify the effect of a virtual realitybased balance rehabilitation program for patients with Menière's disease. METHOD: This observational clinical study included 44 patients aged between 18 and 60 years diagnosed with Menière's disease submitted to a controlled randomized therapeutic intervention. The case and control groups took betahistine and followed a diet. Case group subjects underwent 12 rehabilitation sessions with virtual reality stimuli in a Balance Rehabilitation Unit (BRU TM). Patients were assessed based on DHI scores, the dizziness visual analogue scale, and underwent posturography with virtual reality before and after the intervention. RESULTS: After the intervention, the case group showed significantly lower scores in DHI (p < 0,001) and in the dizziness visual analog scale (p = 0.012), and had significantly greater limit of stability areas (p = 0.016) than controls. CONCLUSION: Virtual reality-based balance rehabilitation effectively improved dizziness, quality of life, and limit of stability of patients with Menière's disease.
Asunto(s)
Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Betahistina/uso terapéutico , Agonistas de los Receptores Histamínicos/uso terapéutico , Enfermedad de Meniere/tratamiento farmacológico , Enfermedad de Meniere/rehabilitación , Terapia de Exposición Mediante Realidad Virtual/métodos , Terapia Combinada , Equilibrio Postural , Resultado del Tratamiento , Pruebas de Función VestibularRESUMEN
Muchas patologías otológicas como la hipoacusia súbita y la enfermedad de Maniere han sido tratadas con corticoides sistémlcos, los que tienen diversos efectos secundarios potencia/mente graves. Los corticoides intratimpánicos son una alternativa en el tratamiento para estas enfermedades del oído interno, con lo que se podría aumentar su efecto al mejorar el perfil farmacocinético de la droga disminuyendo los efectos adversos sistémicos. Para evaluar la evidencia disponible con respecto a la utilidad y racionalidad del uso de esta terapia se realizó una revisión sistemática respecto al tema. Hay pocos trabajos de buena calidad metodológica, los que muestran una efectividad similar de los corticoides intratimpánicos comparados con los sistémicos en terapia primaria y una superioridad ante placebo en terapia de rescate. Por otra parte hay gran variación en los protocolos de administración de la droga y el tipo de corticoide usado. Considerando la alta tasa de resolución espontánea de las patologías en que se ha probado su uso y los resultadosino siempre concordantes de los estudios es difícil establecer la real utilidad de esta terapia. Se requieren estudios de mayor calidad metodológica que ocupen protocolos estandarizados de administración de corticoides intratimpánicos para definir la mejor aplicación de esta modalidad de terapia.
Many otologic diseases as sudden sensorineural hearing loss and Maniere disease had been treated with systemic corticosteroids, which have many potentially serious adverse effects. The intratympanic corticosteroids are an alternative for the treatment of these diseases of the internal ear, having less systemic adverse events and better pharmacoklnetic profile, which may promote its therapeutic effects. We made a systematic review searching the existing evidence about the utility and rationality of the clinical use of this therapy. The few good quality existing trials show a similar effectiveness of the intratympanic corticosteroids compared with the systemic ones for primary therapy and a superiority compared with placebo for rescue therapy. There is a great variation between the different protocols of administration of the intratympanic corticosteroids and the type of corticosteroid used. Considering the high spontaneous resolution of the symptoms in this pathologies and the disparity between the results in the different trials its difficult to establish the real utility of this therapy More good quality studies with standardized protocols areineeded to determine the best clinical application for this kind of therapy.
Asunto(s)
Humanos , Enfermedad de Meniere/tratamiento farmacológico , Glucocorticoides/administración & dosificación , Pérdida Auditiva Súbita/tratamiento farmacológico , Administración Tópica , Glucocorticoides/farmacología , Pérdida Auditiva Sensorineural/tratamiento farmacológicoRESUMEN
OBJECTIVE: To evaluate the effectiveness of low dose transtympanic gentamicin treatment in Meniere's disease. MATERIAL AND METHOD: Prospective study of 20 disable Meniere's patients in Ramathibodi Hospital who received transtympanic gentamicin treatment for Meniere's disease by fixed dose regimen of 12 injections during a period of 4 days. The study took place from March 1999 to December 2004. The hearing and equilibrium guidelines for reporting treatment results in Meniere's disease of the American Academy of Otolaryngology and Head & Neck Surgery (1995) were used. The outcomes of treatment were evaluated at the 6th month. The multivariate repeated measures ANOVA was used for statistical comparisons. RESULTS: During the 5-year period, there were 20 patients, 9 men, and 11 women. The six-month outcomes of vertigo control, the functional level scale and tinnitus score were significantly improved by the treatment. Whereas, the mid frequency pure tone threshold average and the speech discrimination score were not significantly affected. CONCLUSION: Fixed low dose transtympanic gentamicin treatment was found to be an effective treatment option for patients with disabling or intractable Meniere's disease, with a low incidence of hearing deterioration. The use of this method appears to be practical and has been set as the standard protocol replacing the vestibular surgery in Ramathibodi Hospital.
Asunto(s)
Antibacterianos/administración & dosificación , Femenino , Gentamicinas/administración & dosificación , Humanos , Masculino , Enfermedad de Meniere/tratamiento farmacológico , Persona de Mediana Edad , Estudios Prospectivos , Recurrencia , Perfil de Impacto de Enfermedad , Acúfeno/tratamiento farmacológico , Insuficiencia del Tratamiento , Resultado del Tratamiento , Membrana Timpánica/efectos de los fármacos , Vértigo/tratamiento farmacológicoRESUMEN
OBJECTIVE: To evaluate the effectiveness of transtympanic gentamicin treatment in Meniere's disease. MATERIAL AND METHOD: The present study is a prospective study of 8 patients in Ramathibodi Hospital who had transtympanic gentamicin treatment of Meniere's disease by fixed dose regimen of 12 injections during a period of 4 days. The committee on hearing and equilibrium guidelines for reporting treatment results in Meniere's disease of the American Academy of Otolaryngology and Head & Neck Surgery (1995) were used. Paired t-test or Wilcoxon Signed Ranks Test was used for statistical comparisons. RESULTS: Among 8 patients, there were 2 males and 6 females. All patients (100%) had either complete (37.5%) or substantial (62.5%) control of vertigo. Disability was also improved in all of the subjects (100%). Tinnitus was improved in 62.5%. Their tinnitus score and functional level scale were much improved with statistical significance (p = 0.001, p < 0.005, respectively). Hearing was unchanged in 87.5% and slightly worse in 12.5%. This was not significant. CONCLUSION: Transtympanic gentamicin treatment was found to be an effective treatment option for patients with disabling or intractable Meniere's disease, with a low incidence of hearing loss. The use of this method appears to be practical and may replace the vestibular surgery.
Asunto(s)
Adulto , Anciano , Audiometría de Tonos Puros , Femenino , Gentamicinas/administración & dosificación , Humanos , Masculino , Enfermedad de Meniere/tratamiento farmacológico , Persona de Mediana Edad , Estudios Prospectivos , Estadísticas no Paramétricas , Resultado del Tratamiento , Membrana TimpánicaRESUMEN
El tratamiento de la enfermedad de Ménière continúa siendo controversial. Existen muchos tratamientos disponibles con diferentes efectividades. La terapia transtimpánica es una novedosa arma terapéutica que se está introduciendo gradualmente en el campo de la otología. Este estudio pretende: 1) Evaluar la utilidad de la terapia transtimpánica en el tratamiento de la enfermedad de Ménière. 2) Dar a conocer la experiencia de nuestro centro al respecto. Para ello se evaluó retrospectivamente, por medio de una encuesta telefónica, la respuesta clínica de los pacientes con enfermedad de Ménière que recibieron terapia transtimpánica (corticoides y/o gentamicina) entre los años 2002 y 2004. Se estudió a 34 pacientes, con un promedio de edad de 53 años. El 79,4 por ciento (n=27) presentó una respuesta favorable en relación a su sintomatología vestibular (p=0,02) y un 55,9 por ciento (n=19) refirió mejoría total de ella. Cuatro pacientes que no respondieron a corticoides transtimpánicos recibieron gentamicina intratimpánica, llegando a la parálisis vestibular total y mejoría de su sintomatología vestibular. Se concluye que los corticoides transtimpánicos son efectivos en el tratamiento de la sintomatología vestibular en la enfermedad de Ménière. La gentamicina intratimpanica es una alternativa eficaz para los pacientes que no responden a corticoides transtimpánicos.
Asunto(s)
Humanos , Masculino , Adulto , Femenino , Persona de Mediana Edad , Corticoesteroides/uso terapéutico , Enfermedad de Meniere/tratamiento farmacológico , Gentamicinas/uso terapéutico , Vértigo/tratamiento farmacológico , Corticoesteroides/administración & dosificación , Estudios Retrospectivos , Evaluación de Resultados de Intervenciones Terapéuticas , Gentamicinas/administración & dosificación , Inyecciones Intralesiones , Membrana Timpánica , Recolección de Datos , Relación Dosis-Respuesta a Droga , Satisfacción del Paciente/estadística & datos numéricos , Vértigo/etiologíaAsunto(s)
Humanos , Audición , Dexametasona/uso terapéutico , Gentamicinas/uso terapéutico , Membrana Timpánica , Corrección de Deficiencia Auditiva/normas , Vértigo/tratamiento farmacológico , Antibacterianos/administración & dosificación , Antiinflamatorios/administración & dosificación , Dexametasona/administración & dosificación , Enfermedad de Meniere/tratamiento farmacológico , Gentamicinas/administración & dosificación , Vías de Administración de MedicamentosRESUMEN
A betaistinna tem sido amplamente utilizada no tratamento sintomático de pacientes com doença de Meniére e outras sindromes vestibulares periféricas ou centrais. Este artigo apresenta uma revisäo dos aspectos relevantes da experiência clínica internacional e nacional com o uso da betaistina no tratamento da vertigem e sintomas associados. De acordo com a literatura, betaistina é um medicamento eficaz e seguro no controle da vertigem e outras tonturas na doença de Meniére e outras vestibulopatias de origem periférica ou central.(au)
Asunto(s)
Humanos , Enfermedad de Meniere/tratamiento farmacológico , Enfermedades del Laberinto/tratamiento farmacológico , VértigoRESUMEN
Os autores recaptulam diferentes orientaçÆes terapêuticas, indicam os medicamentos que såo utilizados na prática no tratamento da fase crítica e da fase intercrítica, apresentam casuística de 104 casos e relatam os resultados obtidos seguindo a classificaçåo da Academia Americana de Oftalmologia e Otorrinolaringologia
Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto , Enfermedad de Meniere/tratamiento farmacológico , Enfermedad de Meniere/terapiaRESUMEN
Se presenta la experiencia clínica en la intoxicación del oído interno con gentamicina en 10 enfermos portadores de hidropesía edolinfática invalidante. A todos los enfermos se les instiló sulfato de gentamicina en el oído medio en dosis que varían entre 6 y 72 mg con un promedio de 27.1 mg. El 90 por ciento de ellos tuvo un buen resultado, quedando el 60 por ciento asintomático y un 30 por ciento con sintomatología mínima. El otro 10 por ciento no mejoró, permaneciendo su sintomatología sin variación. La audición cayó entre 10 y 20 dB en un 30 por ciento de los pacientes. No hubo cofosis por el tratamiento. En el largo plazo estos buenos resultados no varían
Asunto(s)
Adolescente , Adulto , Persona de Mediana Edad , Gentamicinas/administración & dosificación , Hidropesía Endolinfática/tratamiento farmacológico , Gentamicinas/toxicidad , Gentamicinas/farmacocinética , Vértigo/tratamiento farmacológico , Estudios de Seguimiento , Conducto Coclear/efectos de los fármacos , Enfermedad de Meniere/tratamiento farmacológico , Administración Tópica , Trastornos de la Audición/tratamiento farmacológicoRESUMEN
A manutençäo do equilíbrio é baseada na visäo, impulsos vestibulares, na propriocepçäo e na sensaçäo de pressäo dos pés. Após uma lesäo vestibular unilateral, a compensaçäo vestibular depende das informaçöes de todos esses órgäos. É importante que os exercícios de reabilitaçäo vestibular comecem o mais rápido possível e tenham uma certa intensidade. Os efeitos do treino podem ser avaliados através da história clínica, da eletronistagmografia e posturografia dinâmica, mas mesmo a observaçäo com lentes de Frenzel e observaçöes clínicas do teste de Romberg e Unterberger säo de algum valor. Se há pertubaçäo na percepçäo ou na coordenaçäo central dos órgäos, como o cerebelo, a compensaçäo vestibular näo poderá ser totalmente perfeita. A compensaçäo vestibular observada em um caso e em um grupo de pacientes com doença de Menière incapacitante tratados com gentamicina intratimpânica será sinteticamente delineada